AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00834236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gastric cancer
Description: biomarker in gastric juice, e.g., alpha 1-antitrypsin
Study NCT04450212 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Phase I, Buccal Swab Collection for DNA Isolation
Description: Buccal swab will be taken from study participants for DNA isolation.
Study NCT04450212 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phase II, Vitamin K (Vitacost) Supplementation
Description: 1-mg/day phylloquinone (Vitacost; Natures Life K-1 Phylloquinone) for 10 consecutive days. Each dose will be taken in the morning (\~ 8 am), with one half pint of 2% milk to facilitate absorption. Blood and urine samples collection before and during the vitamin K supplementation period.
Study NCT03154567 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Yohimbine
Description: Yohimbine (0mg, 20mg, or 40 mg) will be administered at 11:00am on each of the experimental sessions.
Study NCT03154567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yohimbine
Description: Yohimbine (0mg, 20mg, or 40 mg) will be administered at 11:00am on each of the experimental sessions.
Study NCT04010838 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal cord stimulation
Description: The spinal cord stimulation(SCS) is a type of implantable neuromodulation device (spinal cord stimulator) that is used to send electrical signals to select areas of the spinal cord (C2-C4 in this study) for the treatment of disorders of consciousness.
Study NCT01681849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Following a three month double blind phase, subjects will be treated with open label paroxetine at a variable dosage of 10-40 mg to reach individual therapeutic levels for three months.
Study NCT01681849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: Following a three month double blind phase, subjects will be treated with open label paroxetine at a variable dosage of 10-40 mg to reach individual therapeutic levels for three months.
Study NCT01681849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paroxetine
Description: Following a three month double blind phase, subjects will be treated with open label paroxetine at a variable dosage of 10-40 mg to reach individual therapeutic levels for three months.
Study NCT01681849 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Positron Emission Tomography (PET) Imaging
Description: Participants will undergo positron emission tomography (PET) imaging of the brain with O-15 radiolabelled water with exposure to traumatic scripts
Study NCT01681849 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) Imaging
Description: Participants will undergo positron emission tomography (PET) imaging of the brain with O-15 radiolabelled water with exposure to traumatic scripts
Study NCT01681849 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Positron Emission Tomography (PET) Imaging
Description: Participants will undergo positron emission tomography (PET) imaging of the brain with O-15 radiolabelled water with exposure to traumatic scripts
Study NCT05080478 — intervention group
Intervention type: DRUG
Intervention: Clopidogrel, Ticagrelor
Description: P2Y12 inhibitors are prescribed following the PCI procedure in patients. Patients are enrolled on the study before administration of the first dose of the drug. Parameters are measured before and after drug initiation.
Study NCT00667043 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil and propofol
Description: Patients will receive: propofol, continuous intravenous infusion, concentration 10 mg/ml, 1-4 mg/kg/hour and remifentanil; continuous intravenous infusion 0,050 mg/ml, 0.1-0.3 microgram/kg/min. Drugs are administered to sedate the patients as part of normal treatment for as long as sedation is needed. Doses are titrated to achieve the desired level of sedation.
Study NCT00667043 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl and midazolam
Description: Patients will receive: midazolam; continuous intravenous infusion, concentration 5 mg/ml, 2-10 mg/hour and fentanyl; continuous intravenous infusion, concentration 0,050 mg/ml, 0.025-0.5 mg/hour. Drugs are administered to sedate the patients as part of normal treatment for as long as sedation is needed. Doses are titrated to achieve the desired level of sedation.
Study NCT00834236 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gastric cancer
Description: biomarker in gastric juice, e.g., alpha 1-antitrypsin
Study NCT02661022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL-401 7 µg/kg/day
Description: SL-401 7 µg/kg/day in combination with pom/dex
Study NCT02661022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL-401 9 µg/kg/day
Description: SL-401 9 µg/kg/day in combination with pom/dex
Study NCT01164657 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: BirthRite
Description: Randomization takes place on admission to delivery unit, study group participants seated on the birthing seat when cervix is fully dilated.
Study NCT01164657 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BirthRite
Description: Randomization takes place on admission to delivery unit, study group participants seated on the birthing seat when cervix is fully dilated.
Study NCT03523650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Oral Tablet
Description: A randomized group of patients with cerebral or spinal cavernous malformations, will receive a Propranolol Oral tablets, tid, for 36 months.
Study NCT03523650 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: A randomized group of patients with cerebral or spinal cavernous malformations, will receive a Placebo Oral Tablet, tid, for 36 months.
Study NCT03044899 — intervention group
Intervention type: PROCEDURE
Intervention: All surgeries in adult patients
Description: All surgeries in adult patients
Study NCT04339218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab will be prescribed and administered at the dose recommended by market authorization.
Study NCT04339218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be prescribed and administered at the dose recommended by market authorization.
Study NCT04339218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed will be prescribed and administered at the dose recommended by market authorization.
Study NCT04339218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be prescribed and administered at the dose recommended by market authorization.
Study NCT04339218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be prescribed and administered at the dose recommended by market authorization.
Study NCT00889382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: Administered orally
Study NCT00889382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered intravenously
Study NCT02864550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: doxycycline 100mg orally daily
Study NCT02864550 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsule identical in appearance, taste, and size to the capsule provided to the intervention group
Study NCT00656539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AzaSite®
Description: Ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for \~26 days
Study NCT03519490 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid Contact Lens
Description: Hybrid Single Vision or Multifocal Contact Lenses in Near Center and Distance Center Designs
Study NCT03519490 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Hybrid Contact Lens
Description: Hybrid Single Vision or Multifocal Contact Lenses in Near Center and Distance Center Designs
Study NCT00840190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P1446A-05
Description: P1446A-05 available as 25mg,50mg,100mg capsule. Subjects will be enrolled at at different dose levels of P1446A-05 to be taken once a day for 14 days followed by 7 days rest.This constitutes one cycle of P1446A-05. Four such cycles will be administered.
Study NCT03901690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betaglucin soluble gel 0.2%
Description: With the prior informed consent of the 51 study participants, 5 grams of 0.2% soluble betaglucin gel will be self-applied every 12 hours for 5 days. Both groups will receive an unlabeled tube so that none of the study participants will know what topical treatments they are receiving.
Study NCT03901690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imiquimod 5% cream
Description: With the prior informed consent of the 51 study participants, 1 gram of 5% imiquimod will be self-applied once a day for 5 days. Both groups will receive an unlabeled tube so that neither study participant knows what topical treatments they are receiving.
Study NCT02169336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Dexmedetomidine
Study NCT02586285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-Adenosyl Methionine
Description: 500mg-1000mg,iv,qd
Study NCT00674973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Participants received erlotinib 150 mg tablet orally once daily.
Study NCT02169336 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Placebo
Study NCT00970788 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video intervention
Description: Video of goals of care
Study NCT03711396 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advance Care Planning Group Visits
Description: Pilot test the Advance Care Planning Group Visit intervention adaptations, called ENgaging in Advance Care planning Talks Group Visit intervention (ENACT Memory Group Visits), to see if it is feasible, acceptable and improves the number of people with amnestic mild cognitive impairment who complete an advance directive (a legal form that describes someone's wishes for future medical care if they are unable to make their own decisions). It will also see how ready individuals are to participate in advance care planning. The overall goal is to improve opportunities for older adults with amnestic mild cognitive impairment to receive medical care that is consistent with their values, goals, and preferences.
Study NCT04327336 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Non invasive ventilation titration
Description: Manual Group: during a complete polysomnography, adding transcutaneous capnography and the basic ventilators curves, the ventilators setting will be adjusted in order to correct respiratory events and patient-ventilator asyncrony. A 10 hours face-to-face investigator training meeting is programmed before opening the inclusion period.
Study NCT04327336 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Automatic Non invasive ventilation titration
Description: Automatic Group: the A40 ventilator in the automatic AVAPS mode will be adjusted in order to achieve 8-10 ml/kg of ideal weight.
Study NCT01148225 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: adalimumab
Description: Adalimumab, pre-filled syringe, administered by SC injection
Study NCT04698551 — intervention group
Intervention type: GENETIC
Intervention: Non invasive prenatal diagnosis
Description: Search for the familial mutation involved in DPN requests from phasing of parental haplotypes by 3rd generation long-fragment DNA sequencing techniques coupled with targeted sequencing of free circulating DNA from maternal plasma.
Study NCT03062176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Anakinra (Kineret)
Study NCT00421967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine, Ketorolac, adrenaline
Description: Infiltration: 150 ml Ropivacaine 2mg/ml added 1 ml Ketorolac 30 mg/ml and 0,5 ml Adrenaline 1 mg/ml Intraarticular infusion: 4 ml/h 384 mg Ropivacaine 60 mg Ketorolac
Study NCT00421967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine Ketorolac
Description: Epidural infusion: 4 ml/h 384 mg Ropivacaine I.V. Ketorolac 90 mg
Study NCT04020016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine ER
Description: Cohort 1: 6-8 subjects will receive 1 dose of 27mg and observed for 4 days. Cohort 2: 6-7 subjects will receive 1 dose of 54 mg and observed for 4 days. Cohort 3: 6-7 subjects will receive 1 dose of 108 mg and observed for 4 days. Cohort 4: 6-8 subjects will receive 1 dose of 162 mg and observed for 4 days. Cohort 5: 6-8 healthy subjects will receive dosing of NAL ER and observed for 4 days.
Study NCT04020016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine ER -
Description: Cohort 6: • 6-8 subjects with mild hepatic impairment and 6-8 subjects with moderate hepatic impairment. Doses will be subsequently escalated for each subject starting at 27 mg on Day 1 to twice daily, 12 hours apart, 27 mg, 54 mg, 108 mg, and 162 mg over 13 days.
Study NCT04559841 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bone substitute; NanoBone®
Description: surgical treatment of peri-implantitis using a regenerative surgical protocol utilizing NanoBone (NB) synthetic bone graft with or without simvastatin.
Study NCT04559841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bone substitute; NanoBone®
Description: surgical treatment of peri-implantitis using a regenerative surgical protocol utilizing NanoBone (NB) synthetic bone graft with or without simvastatin.
Study NCT02111109 — intervention group
Intervention type: DEVICE
Intervention: Side Stream Dark Field Microscopy
Study NCT04986254 — intervention group
Intervention type: OTHER
Intervention: Blood sampling
Description: During a single dosing interval, each participant will have 1 - 8 blood samples taken for each antibiotic. Blood samples (3 mL each) will be drawn from an existing arterial line or central venous catheter. Blood samples will be collected on 2 separate occasions; Occasion 1, between Days 1 - 3 of antibiotic therapy and Occasion 2, between Days 3 - 6 of antibiotic therapy.
Study NCT04986254 — intervention group
Intervention type: OTHER
Intervention: Epithelial lining fluid sampling
Description: Epithelial lining fluid will be sampled using either a bronchoalveolar lavage (BAL) or mini-BAL technique, in accordance with the preferred procedure in participating sites. 3 BAL or mini-BAL samples will be collected over 2 separate occasions; Occasion 1, between Days 1 - 3 of antibiotic therapy and Occasion 2, between Days 3 - 6 of antibiotic therapy.
Study NCT04986254 — intervention group
Intervention type: OTHER
Intervention: Urine sampling
Description: The total urine volume over the duration of the dosing interval will be collected on the two sampling occasions for a calculated urinary creatinine clearance measurement.
Study NCT01652404 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided treatment
Description: The antibiotics duration will be determined by the serum procalcitonin level at day 5, 7 and 9.
Study NCT01652404 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: The antibiotics duration will be determined by treating physician.
Study NCT01448304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alirocumab SAR236553 (REGN727)
Description: Pharmaceutical form:Solution Route of administration: Subcutaneous
Study NCT02019836 — intervention group
Intervention type: OTHER
Intervention: Determining maternal and neonatal vitamin D levels
Study NCT02886364 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Adapted Safe Childbirth Checklist
Description: The World Health Organization has created and endorsed the WHO Safe Childbirth Checklist as a tool for improving quality of care around childbirth. This tool has been modified to the context in Mexico by another group of investigators at the National Institute of Public Health. Our team expanded the Mexican version of the WHO Safe Childbirth Checklist to include indicators around respectful maternity care.
Study NCT01046669 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TORAYMYXIN PMX-20R (PMX cartridge)
Description: TORAYMYXIN PMX-20R (PMX cartridge), Extracorporeal hemoperfusion device. Each treatment will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 ml/minute, (range of 80 to 120 ml/minute).
Study NCT01046669 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard medical care for septic shock
Description: Standard medical care for septic shock
Study NCT01046669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard medical care for septic shock
Description: Standard medical care for septic shock
Study NCT02239042 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LLLT
Description: The patients allocated for the test group received the following protocol for laser application: Five (5) points of irradiation were performed. The irradiation was performed with a ASGaAl diode laser that continuously emitted a wavelength of 660 nm. 30 mW was used for 20 seconds, and the total applied energy density (fluence) was 15 J/cm2 (3 J/cm2 per point and an application time of 4 seconds per point). The applications were performed using punctual contact (to reduce reflection) with the tip perpendicular to the gingival tissue. Laser therapy was initiated in the immediate postoperative period (just after sutures) and was followed by seven more applications performed every other day, with a total of 8 laser applications. The power of the equipment was calibrated prior to each application. The patients allocated to the control group received sham irradiation. For this, black rubber protection was placed at the tip of the laser device, which did not allow the light to reach the tissue
Study NCT02239042 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: LLLT
Description: The patients allocated for the test group received the following protocol for laser application: Five (5) points of irradiation were performed. The irradiation was performed with a ASGaAl diode laser that continuously emitted a wavelength of 660 nm. 30 mW was used for 20 seconds, and the total applied energy density (fluence) was 15 J/cm2 (3 J/cm2 per point and an application time of 4 seconds per point). The applications were performed using punctual contact (to reduce reflection) with the tip perpendicular to the gingival tissue. Laser therapy was initiated in the immediate postoperative period (just after sutures) and was followed by seven more applications performed every other day, with a total of 8 laser applications. The power of the equipment was calibrated prior to each application. The patients allocated to the control group received sham irradiation. For this, black rubber protection was placed at the tip of the laser device, which did not allow the light to reach the tissue
Study NCT02522052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blue mussel diet
Description: 5 meals a week containing blue mussels
Study NCT02522052 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meat/Control diet
Description: 5 meals a week containing meat
Study NCT00674973 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received placebo matching to erlotinib 150 mg tablet orally once daily.
Study NCT04237012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextenza 0.4Mg Intracanalicular Insert
Description: all patients will receive Intracanalicular dexamethasone, 0.4mg insert lower punctum and able to use over the counter artificial tears PRN at patient discretion
Study NCT04237012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Over the counter Artificial tears
Description: over the counter artificial tears PRN at patient discretion
Study NCT04285099 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application of dual system in frequency A
Description: The investigators set two values of frequency (130, 60Hz) in IPG and allow the patients to change the frequencies freely using the patient controller. Technician randomly sets 130 Hz, 60HZ to A or B.
Study NCT04285099 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application of dual system in frequency B
Description: The investigators set two values of frequency (130, 60Hz) in IPG and allow the patients to change the frequencies freely using the patient controller. Technician randomly sets 130 Hz, 60HZ to A or B.
Study NCT02804529 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Veress needle
Study NCT01155219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Geltim LP 1 mg/g
Description: one drop in the conjunctival sac of each eye in the morning (84 days).
Study NCT01155219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xalatan
Description: one drop in the conjunctival sac of each eye in the morning (84 days).